Dual Antiplatelet Therapy Guided by CYP2C19 Polymorphisms after Implantation of Second-Generation Drug-Eluting Stents for Management of Acute Coronary Syndrome

Prasugrel, a novel P2Y12 receptor inhibitor, is administered to patients with acute coronary syndrome (ACS) after percutaneous coronary intervention (PCI), but it can increase the risk of bleeding. The Japanese exhibit weaker responses to clopidogrel than other races because of CYP2C19 polymorphisms...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	International Heart Journal 2018/01/31, Vol.59(1), pp.21-26
Hauptverfasser:	Ozawa, Takuya, Suda, Masayoshi, Ikegami, Ryutaro, Takano, Toshiki, Wakasugi, Takayuki, Yanagawa, Takao, Tanaka, Komei, Ozaki, Kazuyuki, Hirono, Satoru, Minamino, Tohru
Format:	Artikel
Sprache:	eng
Schlagworte:	Acute coronary syndromes Antiplatelet therapy Cerebrovascular system Clopidogrel Drug delivery Hemorrhage Implants Major adverse cardiovascular/cerebrovascular event (MACCE) Multivariate analysis Patients Percutaneous coronary intervention (PCI) Prasugrel
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!